NeuroBo Pharmaceuticals Together With Dong-A ST and ImmunoForge Announces Joint Research Agreement To Develop A Long-Acting Once-Monthly Formulation of DA-1726 For The Treatment Of Obesity; Financial Terms Of The Agreement Were Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals, Dong-A ST, and ImmunoForge have announced a joint research agreement to develop a long-acting, once-monthly formulation of DA-1726 for obesity treatment. The collaboration will leverage ImmunoForge's ELP platform technology to significantly increase the drug's half-life. Financial terms were not disclosed.
August 06, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroBo Pharmaceuticals has entered a joint research agreement with Dong-A ST and ImmunoForge to develop a long-acting, once-monthly formulation of DA-1726 for obesity treatment, leveraging ImmunoForge's ELP platform technology.
The partnership and development of a novel drug formulation for obesity treatment is a significant step for NeuroBo Pharmaceuticals. This could potentially lead to positive market sentiment and an increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100